David Ashkin

3.3k total citations
39 papers, 1.8k citations indexed

About

David Ashkin is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, David Ashkin has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Infectious Diseases, 25 papers in Epidemiology and 14 papers in Surgery. Recurrent topics in David Ashkin's work include Tuberculosis Research and Epidemiology (29 papers), Mycobacterium research and diagnosis (14 papers) and Pneumocystis jirovecii pneumonia detection and treatment (10 papers). David Ashkin is often cited by papers focused on Tuberculosis Research and Epidemiology (29 papers), Mycobacterium research and diagnosis (14 papers) and Pneumocystis jirovecii pneumonia detection and treatment (10 papers). David Ashkin collaborates with scholars based in United States, India and Saudi Arabia. David Ashkin's co-authors include Elena S. Hollender, Arthur E. Pitchenik, Masahiro Narita, Denis Jones, David Bernstein, Jerry Jean Stambaugh, Charles A. Peloquin, Michael Lauzardo, Maria José Míguez‐Burbano and Gail Shor‐Posner and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Clinical Infectious Diseases and CHEST Journal.

In The Last Decade

David Ashkin

37 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Ashkin United States 20 1.2k 1.0k 640 167 160 39 1.8k
Majid Marjani Iran 23 1.3k 1.1× 795 0.8× 419 0.7× 91 0.5× 92 0.6× 170 1.8k
Kazunari Tsuyuguchi Japan 14 1.1k 0.9× 1.1k 1.0× 442 0.7× 106 0.6× 65 0.4× 85 1.5k
Giorgio Barbarini Italy 31 762 0.6× 1.4k 1.3× 343 0.5× 85 0.5× 113 0.7× 88 2.5k
Martina Sterneck Germany 36 448 0.4× 2.5k 2.4× 1.7k 2.7× 136 0.8× 124 0.8× 165 4.7k
Maurizio Bonacini United States 30 649 0.5× 2.1k 2.0× 368 0.6× 427 2.6× 185 1.2× 72 3.0k
Heping Xiao China 21 670 0.6× 575 0.5× 341 0.5× 99 0.6× 84 0.5× 77 1.2k
Katsuji Teruya Japan 23 999 0.8× 773 0.7× 146 0.2× 104 0.6× 223 1.4× 116 1.8k
Gregory P. Bisson United States 23 1.4k 1.1× 1000 1.0× 317 0.5× 39 0.2× 70 0.4× 70 1.9k
Getachew Aderaye Ethiopia 24 1.1k 0.9× 806 0.8× 347 0.5× 334 2.0× 166 1.0× 51 1.6k
Ronan Breen United Kingdom 23 976 0.8× 890 0.8× 748 1.2× 42 0.3× 141 0.9× 48 1.8k

Countries citing papers authored by David Ashkin

Since Specialization
Citations

This map shows the geographic impact of David Ashkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ashkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ashkin more than expected).

Fields of papers citing papers by David Ashkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ashkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ashkin. The network helps show where David Ashkin may publish in the future.

Co-authorship network of co-authors of David Ashkin

This figure shows the co-authorship network connecting the top 25 collaborators of David Ashkin. A scholar is included among the top collaborators of David Ashkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ashkin. David Ashkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ashkin, David, et al.. (2023). Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration Monitoring. Open Forum Infectious Diseases. 10(6). ofad237–ofad237. 1 indexed citations
3.
Barber, Daniel L., Shunsuke Sakai, Ragini R. Kudchadkar, et al.. (2019). Tuberculosis following PD-1 blockade for cancer immunotherapy. Science Translational Medicine. 11(475). 132 indexed citations
4.
Mase, Sundari, David Ashkin, Kenneth G. Castro, et al.. (2019). Tuberculosis Regional Training and Medical Consultation Centers in the United States: Characteristics, outcomes, and quality of medical consultations, June 1, 2010 — May 31, 2014. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 17. 100114–100114. 3 indexed citations
5.
6.
Hollender, Elena S., Karen Farrell, Jerry Jean Stambaugh, et al.. (2009). Pharmacokinetic Evaluation of Rifabutin in Combination with Lopinavir‐Ritonavir in Patients with HIV Infection and Active Tuberculosis. Clinical Infectious Diseases. 49(9). 1305–1311. 63 indexed citations
7.
Campos, Michael, Andrew A. Quartin, Eliana Mendes, et al.. (2008). Feasibility of Shortening Respiratory Isolation with a Single Sputum Nucleic Acid Amplification Test. American Journal of Respiratory and Critical Care Medicine. 178(3). 300–305. 28 indexed citations
8.
Quartin, Andrew A., et al.. (2008). Acute Lung Injury Outside of the ICU. CHEST Journal. 135(2). 261–268. 19 indexed citations
9.
10.
Míguez‐Burbano, Maria José, et al.. (2005). Non-tuberculous mycobacteria disease as a cause of hospitalization in HIV-infected subjects. International Journal of Infectious Diseases. 10(1). 47–55. 47 indexed citations
11.
Zhu, Min, W. J. Burman, Jeffrey R. Starke, et al.. (2004). Pharmacokinetics of ethambutol in children and adults with tuberculosis.. PubMed. 8(11). 1360–7. 62 indexed citations
12.
Míguez‐Burbano, Maria José, et al.. (2003). Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addiction Biology. 8(1). 39–43. 94 indexed citations
13.
Narita, Masahiro, Michie Hisada, Jerry Jean Stambaugh, et al.. (2001). Tuberculosis Recurrence: Multivariate Analysis of Serum Levels of Tuberculosis Drugs, Human Immunodeficiency Virus Status, and Other Risk Factors. Clinical Infectious Diseases. 32(3). 515–517. 33 indexed citations
14.
Narita, Masahiro, Pedro L. Alonso, Michael Lauzardo, et al.. (2001). Treatment Experience of Multidrug-Resistant Tuberculosis in Florida, 1994–1997. CHEST Journal. 120(2). 343–348. 49 indexed citations
15.
Jones, Denis, et al.. (2000). Mesothelial Cells in Tuberculous Pleural Effusions of HIV-Infected Patients. CHEST Journal. 117(1). 289–291. 17 indexed citations
16.
Narita, Masahiro, Jerry Jean Stambaugh, Elena S. Hollender, et al.. (2000). Use of Rifabutin with Protease Inhibitors for Human Immunodeficiency Virus-Infected Patients with Tuberculosis. Clinical Infectious Diseases. 30(5). 779–783. 55 indexed citations
17.
Lauzardo, Michael & David Ashkin. (2000). Phthisiology at the Dawn of the New Century. CHEST Journal. 117(5). 1455–1473. 41 indexed citations
18.
Jones, Denis, et al.. (1998). Antituberculosis Drug–induced Hepatotoxicity: The Role of Hepatitis C Virus and the Human Immunodeficiency Virus. American Journal of Respiratory and Critical Care Medicine. 157(6). 1871–1876. 215 indexed citations
19.
Narita, Masahiro, David Ashkin, Elena S. Hollender, & Arthur E. Pitchenik. (1998). Paradoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDS. American Journal of Respiratory and Critical Care Medicine. 158(1). 157–161. 460 indexed citations
20.
Ahmed, Tanveer, et al.. (1997). Inhibition of Antigen-Induced Acute Bronchoconstriction, Airway Hyperresponsiveness, and Mast Cell Degranulation by a Nonanticoagulant Heparin: Comparison With a Low Molecular Weight Heparin. American Journal of Respiratory and Critical Care Medicine. 155(6). 1848–1855. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Majid Marjani Breakdown of academic impact, for papers by Kazunari Tsuyuguchi Breakdown of academic impact, for papers by Giorgio Barbarini Breakdown of academic impact, for papers by Martina Sterneck Breakdown of academic impact, for papers by Maurizio Bonacini Breakdown of academic impact, for papers by Heping Xiao Breakdown of academic impact, for papers by Katsuji Teruya Breakdown of academic impact, for papers by Gregory P. Bisson Breakdown of academic impact, for papers by Getachew Aderaye Breakdown of academic impact, for papers by Ronan Breen
Rankless by CCL
2026